To evaluate the efficacy of Switch therapy for community-acquired @entity55 , we conducted a prospective randomized controlled study in thirty-two hospitalized @entity1 . These cases corresponded to Fine's risk classes II to IV. Using a table of random numbers, sixteen @entity1 were assigned to a Switch therapy group, and the other sixteen, to a clinical pathway group. Both groups initially received intravenous antimicrobials. Within the Switch therapy group, when all the @entity1 were afebrile for more than sixteen hours, their intravenous antimicrobials were switched to oral, and the @entity1 were discharged on the following day. For all @entity1 in the clinical pathway group, the critical pathway was defined as an eight-day planned hospitalization, with a time-task matrix formatted for disease treatment, laboratory testing, physical examination, @entity26 saturation monitoring, ambulation, diet, @entity1 education and clinical outcome. Switch therapy reduced the period of intravenous antimicrobial administration from 7.6 days to 4.0 days (p < 0.0001). The period required to switch to oral antimicrobials decreased from 8.3 days to 4.8 days (p < 0.0001); hospital stay length, from 9.8 days to 6.5 days (p = 0.0001); and medical resource utilization, from 330, 373 to 227,768 Japanese yen (p = 0.0002). No @entity1 from either group required readmission. In conclusion, Switch therapy was more efficient than management with a clinical pathway for mild to moderate community-acquired @entity55 in hospitalized @entity1 .

[The efficacy of switch therapy in community-acquired XXXX in Japan].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']
@entity55 :: (MESH:D011014,Disease) :: ['pneumonia']
